Placebo matching with INX-08189: Clinical Trials

2 trials of Placebo matching with INX-08189, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Completed 1
Phase 21Terminated 1

Follow Placebo matching with INX-08189: new trials by email Literature Review of Placebo matching with INX-08189 trials Research Report on Placebo matching with INX-08189

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin
INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a - Hepatitis C
Phase 2TerminatedBristol-Myers Squibb2102012-05-012015-11-04
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
INX-08189, Placebo matching with INX-08189, Ribavirin - HCV (Genotype 1)
Phase 1CompletedBristol-Myers Squibb702010-10-012012-07-12

Conditions studied

Hepatitis C (2)  ·  Hepatitis, Chronic (1)

Sponsors

Bristol-Myers Squibb (2)

Countries

United States (2)  ·  Puerto Rico (1)